Liquidia (LQDA) Cash from Operations Growth (3y) (2023 - 2026)
Powered by 
Analysis
Liquidia (LQDA) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.43 Bn | 625.67 Bn | 17.26 Bn | 27.24% |
| 2 | AbbVie | 442.46 Bn | 435.89 Bn | 12.70 Bn | -18.38% |
| 3 | Merck | 366.77 Bn | 359.63 Bn | 12.21 Bn | 13.18% |
| 4 | Novartis Ag | 266.59 Bn | 258.90 Bn | 11.24 Bn | 18.04% |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 39.10% |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | 56.97% |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn | 18.31% |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn | 43.42% |
| 10 | Liquidia | 6.11 Bn | 5.82 Bn | 160.92 Mn | 154.18% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 154.18% |
| Mar 31, 2026 | 102.19% |
| Dec 31, 2025 | 126.45% |
| Sep 30, 2025 | -19.16% |
| Jun 30, 2025 | -67.32% |
| Mar 31, 2025 | -46.38% |
| Dec 31, 2024 | -40.16% |
| Sep 30, 2024 | -62.63% |
| Jun 30, 2024 | -40.00% |
| Mar 31, 2024 | -26.15% |
| Dec 31, 2023 | -4.29% |
| Sep 30, 2023 | 2.59% |
| Jun 30, 2023 | 24.85% |
| Mar 31, 2023 | 16.33% |